← Johnson & Johnson overview

Johnson & Johnson vs Euro/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Johnson & Johnson (JNJ)

Q3 2026
▲3

J&J Beats, Raises Guidance, Settles Talc, But Valuation Stretched

  • Q2 Beat, Guidance Raised, Dividend Hiked J&J beat second-quarter estimates, raised full-year revenue guidance to about $101 billion, and increased its dividend for the 64th straight year, signaling steady profit growth and shareholder returns.

    This is the core new financial update that directly boosted investor confidence in the quarter.

  • $5.5B Talc Settlement Removes Major Legal Overhang A $5.5 billion settlement resolved roughly 76,000 talc claims, removing a large legal cloud that had weighed on the stock and reducing uncertainty about future payouts.

    This is a major new event that reduces a key risk factor for the company.

  • Oncology Strength and New Drug Approvals Strong sales from cancer drugs Darzalex, Tremfya, and Erleada, plus new approvals IMAAVY, ICOTYDE, and THERMOCOOL, support future revenue growth and pipeline momentum.

    These new product successes are a key driver of expected future earnings.

  • Growth Prospects vs. Valuation and Competitive Risks A planned ~$20B DePuy Synthes sale and pipeline deals support growth, but MedTech lagged, Firefly Bio dilutes EPS by ~$0.46, Stelara biosimilar competition accelerates, and rivals beat Tecvayli in myeloma. Valuation trades ~40% above GF Value, limiting upside.

    This captures the main counterweights that could cap gains despite positive developments.

August 2026
▲2▼2

J&J's August–October 2026: New Drug Approvals and Pipeline Gains, but Valuation Stretched

  • New Drug Approvals and Pipeline Expansion J&J won approvals for IMAAVY, China's Icotyde, expanded Stelara use, and the THERMOCOOL catheter, while the OTTAVA surgical robot advanced. These new products strengthen future growth prospects.

    This point highlights the key new product approvals that drove positive sentiment during the period.

  • Oncology Sales Growth and Guidance Raise Oncology sales grew 16%, and J&J raised full-year guidance and lifted its dividend for the 64th straight year. This reflects strong business performance and shareholder returns.

    This point captures the financial performance and guidance that supported the stock.

  • Valuation Stretched Above Fair Value JNJ trades roughly 40% above its GF Value estimate, meaning good news is largely priced in. This limits upside and increases risk of a pullback.

    This point provides a key counterweight, showing the stock may be overvalued.

  • Stelara Biosimilar Competition Accelerates Stelara biosimilar competition is accelerating, slowing overall growth despite new drugs cushioning the impact. Icotyde may also cannibalize Tremfya sales.

    This point highlights a significant headwind that could pressure future revenue.

Latest
▲3

J&J pipeline wins and analyst upgrades offset Stelara biosimilar drag

  • New drug data strengthen growth pipeline J&J reported positive new data for IMAAVY in myasthenia gravis, TECVAYLI/CARVYKTI/TREMFYA in myeloma and arthritis, and two-year ICOTYDE results in psoriasis. These support expanded use and future sales, helping replace revenue lost from older drugs.

    Shows the main new scientific catalysts that can lift future revenue and investor confidence.

  • FDA approves dual-energy heart catheter The FDA approved J&J's THERMOCOOL SMARTTOUCH SF dual-energy catheter, which lets doctors use two energy types in one device. This expands J&J's heart-device lineup and could win share in a growing market, supporting MedTech sales.

    A concrete new product approval that adds a near-term revenue driver in MedTech.

  • Analyst upgrades on defensive appeal and new drugs BofA raised its J&J target to $278, citing a re-rating of defensive stocks and higher ICOTYDE forecasts. Another analyst sees a possible all-time high by year-end. Higher targets can pull more buyers into the stock.

    Captures the main new sell-side actions that influence near-term investor sentiment and demand for the shares.

  • Oncology strength vs. Stelara biosimilar pressure J&J expects strong oncology growth from Darzalex, Carvykti and others, but Stelara's patent expiry is cutting sales faster this quarter, with rivals launching copies. The net effect is slower overall growth, though new drugs are cushioning the blow.

    The key counterweight: it explains why growth is not even faster and keeps the stock from rising more.

September 2026
▲3▼1

J&J advances pipeline and growth plans, but faces competitive setbacks

  • Pipeline and growth outlook strengthened J&J struck a CAR-T deal with Sail Biomedicines, reported positive lung-cancer and depression trial results, and reaffirmed double-digit growth guidance by 2030. These moves bolster future revenue prospects.

    This point highlights new pipeline and guidance developments that could drive future growth.

  • New drug approvals and trial success The FDA approved ICOTYDE for psoriasis, offering a new revenue stream as Stelara loses patent protection. Caplyta met its goal in a bipolar I mania trial, potentially adding up to $5 billion in peak sales.

    These approvals and trial results represent new revenue opportunities for J&J.

  • DePuy Synthes sale to raise cash J&J is nearing a ~$20 billion sale of DePuy Synthes to Apollo, which would raise cash for faster-growing areas. This strategic move could fund future growth initiatives.

    The potential sale is a new strategic action that could impact J&J's capital allocation.

  • Competitive and trial setbacks AbbVie's etentamig beat J&J's Tecvayli in myeloma, rivals are advancing in ulcerative colitis, and a licensed depression drug failed its Phase 2 trial. These setbacks pose risks to J&J's market position.

    These competitive and clinical failures could negatively impact J&J's growth and stock price.

▲3▼1

J&J advances pipeline, nears $20B orthopedics sale

  • FDA approves ICOTYDE for psoriasis The FDA approved ICOTYDE, a once-daily pill for moderate-to-severe plaque psoriasis. This new immunology drug can help replace sales lost from Stelara's patent expiry, adding a fresh revenue stream and supporting J&J's long-term growth.

    New US approval expands J&J's immunology franchise and offsets Stelara loss.

  • Caplyta succeeds in bipolar I mania trial J&J's Caplyta hit its main goal in a late-stage trial for bipolar I mania, with symptom relief seen by day three. If approved, this could add up to $5 billion in peak sales, strengthening J&J's neuroscience business.

    Positive Phase 3 data supports label expansion and potential $5B peak sales.

  • Apollo in talks to buy DePuy Synthes for ~$20B Apollo Global is in talks to buy J&J's orthopedics unit, DePuy Synthes, for close to $20 billion. A sale would give J&J cash to invest in faster-growing areas like oncology and immunology, simplifying the company.

    Potential $20B sale accelerates pivot to higher-growth areas and simplifies J&J.

  • Depression drug fails Phase 2 trial A depression drug J&J licensed, JNJ-5120/PIPE-307, missed its primary goal in a mid-stage trial. This is a setback for J&J's pipeline, though the company is still analyzing the full data before deciding next steps.

    Pipeline setback creates a negative counterweight to the positive pipeline news.

▲1▼1

J&J advances pipeline and weighs $20B orthopedics sale

  • Pipeline and growth outlook strengthen J&J struck a CAR-T deal with Sail Biomedicines, reported strong lung-cancer and depression trial results, and reaffirmed guidance with double-digit growth expected by 2030. These add future sales and support the stock.

    Shows the main positive force behind JNJ's price this period.

  • Possible $20B sale of DePuy Synthes J&J is in talks to sell its orthopedics unit for about $20 billion, but could spin it off or talks could fail. A sale would simplify the company and raise cash, but the outcome is unclear, so the stock impact is uncertain.

    A major capital move that could reshape J&J and affect its price.

  • Competition in myeloma and ulcerative colitis AbbVie's etentamig showed positive Phase 3 results against J&J's Tecvayli, and rivals are advancing in ulcerative colitis. More competition could slow sales of J&J's drugs in these markets.

    A real counterweight to the positive pipeline news.

▲3

J&J wins new drug approvals, but valuation and self-cannibalization temper gains

  • FDA approves IMAAVY as first treatment for warm autoimmune hemolytic anemia The FDA approved J&J's IMAAVY as the first-ever treatment for warm autoimmune hemolytic anemia, a rare blood disease. This opens a brand-new market for a drug already approved for myasthenia gravis, adding future sales and reinforcing J&J's pipeline strength.

    This is a new regulatory approval that expands J&J's addressable market and supports future revenue growth.

  • China approves oral psoriasis drug Icotyde, opening a large market China approved J&J's once-daily oral psoriasis pill Icotyde, targeting over 8.4 million patients there. A pill is more convenient than injections, so it could become a blockbuster and take share from rivals, though it may also pull some patients away from J&J's own injectable Tremfya.

    This is a new geographic approval that opens a major market but carries a self-cannibalization risk.

  • FDA expands Stelara approval to pediatric ulcerative colitis The FDA expanded Stelara's use to children aged two and older with ulcerative colitis. This adds a new patient group for an existing drug, providing a modest sales boost and showing J&J continues to squeeze more value from its older medicines.

    This is a new label expansion that adds a pediatric indication, supporting incremental revenue.

  • New approvals face high valuation and commercial challenges J&J's stock trades about 40% above its GF Value estimate, so good news is already priced in. The new anemia drug faces adoption and reimbursement hurdles, and the China psoriasis pill could just shift sales from Tremfya. These factors limit how much the approvals can lift the stock near term.

    This is the key counterweight: high valuation and commercial execution risks mean the new approvals may not translate into immediate stock gains.

▲4

J&J lifts guidance, raises dividend, expands cancer and device pipeline

  • Guidance raised again on strong Q2 J&J lifted full-year sales guidance to about $101.1 billion and adjusted earnings to $11.68 a share, after quarterly sales of $25.3 billion beat expectations. Higher profit expectations make the stock more attractive and support its price.

    This is the period's core new financial event and directly lifts earnings expectations.

  • Dividend raised for 64th straight year J&J raised its quarterly dividend 3.1% to $1.34 a share, the 64th year in a row, backed by free cash flow that jumped to about $8.7 billion. A growing payout draws income investors and signals confidence in future cash.

    A new dividend increase is a fresh, concrete signal of financial strength that supports the stock.

  • Cancer and device pipeline keeps expanding New wins include European approval of TECVAYLI plus daratumumab for myeloma, FDA clearance for the AI-powered MONARCH QUEST 3 bronchoscopy system, and late-stage development of antidepressant Seltorexant. Each adds future sales and reinforces growth beyond Stelara.

    These are new approvals and pipeline advances that extend J&J's growth story.

  • Underlying growth is double-digit ex-Stelara Reported sales rose 5.6%, but excluding the shrinking Stelara generics drag, growth was double-digit. Tremfya jumped 71% to a first $2 billion quarter, and immunology and neuroscience are becoming new engines. This shows the core business is healthier than the headline.

    It explains why the Stelara patent cliff is no longer the dominant story and supports the bull case.

▲4

Analysts lift JNJ targets as talc deal and cancer sales build

  • Analyst price targets jump after strong Q2 A wave of firms (Scotiabank, Citi, Morgan Stanley, Goldman and others) raised JNJ price targets to roughly $260–$305, lifting the average fair value estimate to about $270.59 from $252.87. Higher targets pull money into the stock and support the share price.

    This is the period's clearest new price driver: broad analyst upgrades after earnings.

  • Talc settlement removes a long-running legal cloud J&J agreed to pay up to $5.5 billion to settle tens of thousands of talc lawsuits, provided at least 95% of claimants accept. Ending years of litigation makes J&J less risky to own and gives investors clearer visibility on future cash costs.

    The settlement is the biggest new event of the period and directly reduces legal risk weighing on the stock.

  • Cancer drug sales keep growing fast J&J's oncology revenue rose 16% to $7.4 billion, led by Darzalex (up about 18% to over $4 billion) and Erleada. Cancer is now nearly 29% of total sales, and J&J targets over $50 billion in annual cancer sales by 2030, supporting long-term growth.

    Oncology is J&J's main growth engine and the fresh sales figures show it is still accelerating.

  • OTTAVA surgical robot seen as a new growth market J&J's FDA-cleared OTTAVA robotic surgery system is being framed as a breakthrough that opens a new device market and could challenge Intuitive Surgical. Investors are watching adoption and orders, which could add a fresh revenue stream over time.

    The robot is a new product story that changes how investors value J&J's device business.

July 2026
▲3▼1

J&J Beats Q2, Raises Guidance, Settles Talc, But MedTech Lags

  • Q2 Beat, Raised Guidance, Dividend Increase J&J beat Q2 estimates for the ninth straight quarter, raised full-year revenue guidance to about $101 billion, and lifted its dividend for the 64th year. This shows steady profit growth and rewards shareholders.

    These are new financial results and capital returns that directly boost investor confidence.

  • Talc Settlement Removes Major Legal Overhang J&J settled about 76,000 talc claims for $5.5 billion, removing a large legal cloud. This reduces uncertainty that had weighed on the stock for years.

    The settlement is a new event that significantly lowers legal risk, a key prior concern.

  • Oncology Strength and Pipeline Expansion Darzalex, Tremfya, and Erleada offset Stelara's patent cliff. FDA clearance of the OTTAVA surgical robot, strong myeloma data, and new cancer deals expand future growth prospects.

    These new product advances and deals drive future revenue and offset patent losses.

  • MedTech Weakness and Firefly Bio EPS Dilution MedTech lagged with Abiomed heart-pump weakness and slowing electrophysiology growth. The Firefly Bio acquisition dilutes 2026 earnings by about $0.46 per share, and an Illinois court upheld a $45 million talc verdict, keeping some legal risk alive.

    These are new negative developments that partially offset the positive news and could pressure the stock.

▲3▼1

J&J settles talc for $5.5B, raises outlook, expands cancer pipeline

  • Talc settlement removes legal overhang J&J agreed to pay $5.5 billion to settle about 76,000 ovarian talc claims, with payments starting no earlier than 2027. This removes a huge legal cloud that had weighed on the stock for years, making J&J less risky to own and lifting shares over 2%.

    This is the single biggest new event of the period and directly reduces JNJ's legal risk, a key overhang.

  • Raised guidance and record Q2 sales J&J posted record quarterly sales of $25.3 billion, up 6.6%, and raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. This puts J&J on track to top $100 billion in annual sales for the first time, boosting confidence in management.

    The raised outlook and record sales are new this period and directly support the stock's long-term value.

  • New cancer pipeline deals and FDA progress J&J partnered with Sail Biomedicines on in vivo CAR-T therapies, completed the $1 billion Firefly Bio acquisition, and won FDA Priority Review for RYBREVANT FASPRO in head and neck cancer. These expand the cancer pipeline and could drive future sales.

    These are new pipeline and regulatory wins that reinforce J&J's oncology growth story.

  • MedTech weakness and Firefly dilution MedTech sales missed estimates as Abiomed's heart pump sales fell 2% after a UK study, and J&J tempered its Abiomed outlook. The Firefly Bio deal will dilute 2026 EPS by about $0.46. These weigh on near-term results and raise doubts about the devices business.

    This is the main counterweight: a real weakness in MedTech and a dilution hit that could pressure the stock.

▲4

J&J's oncology pipeline and surgical robot drive growth

  • FDA clears OTTAVA robotic surgery system J&J won FDA authorization for its OTTAVA robotic surgical system, the first table-integrated soft-tissue robot. This opens a new medical-device growth market and could challenge Intuitive Surgical, adding a fresh revenue stream that supports the stock.

    New regulatory approval creates a new device growth engine, directly answering what is driving JNJ now.

  • TECVAYLI plus TALVEY cuts myeloma death risk 89% A Phase 3 trial showed the TECVAYLI-TALVEY combo cut the risk of progression or death by 89% in earlier-line multiple myeloma. Strong data like this supports wider use and future sales, reinforcing J&J's cancer leadership.

    New clinical data strengthens the oncology pipeline, a key growth driver for JNJ.

  • Oncology sales offset Stelara patent cliff Q2 Innovative Medicine sales rose 6.8% on strong Darzalex, Tremfya and Erleada demand, even as Stelara fell 55% on generics. J&J aims for $50 billion in annual cancer sales by 2030, showing the growth story is intact.

    Explains the core earnings engine and how new drugs are replacing lost revenue, central to JNJ's outlook.

  • Ninth straight earnings beat, guidance raised J&J beat Q2 estimates for the ninth quarter in a row and raised full-year sales and profit guidance, putting it on track to top $100 billion in revenue for the first time. Consistent beats build confidence in management and support the stock.

    Repeated earnings beats and raised guidance are a major reason investors are positive on JNJ right now.

▲3▼1

J&J beats Q2, raises guidance, but MedTech slowdown drags stock

  • Q2 earnings beat and raised 2026 guidance J&J reported Q2 sales of $25.31 billion, up 6.6%, and adjusted EPS of $2.90, both above estimates. It raised full-year revenue guidance to about $101.1 billion and EPS to $11.68. Strong drug sales, especially Tremfya and Darzalex, drove the beat, supporting the stock's long-term value.

    This is the period's biggest new event and directly shows J&J's financial health, a key price driver.

  • MedTech slowdown raises doubts about balanced growth Despite the overall beat, J&J's MedTech unit grew only 3.6% operationally, with cardiovascular sales falling 2% and electrophysiology growth slowing to 3.1%. The stock dropped 2.7% as investors worried that pharma strength is masking weakness in devices, threatening the two-engine growth story.

    This is the main counterweight this period and explains why the stock fell despite the earnings beat.

  • DePuy Synthes acquires Expanding Innovations for spine portfolio J&J's DePuy Synthes acquired Expanding Innovations, adding expandable implant technology for spine surgery. This strengthens its spine portfolio and competitive position in a growing market, supporting future MedTech sales and offsetting some weakness.

    A new acquisition that shows J&J is investing to strengthen its MedTech business, relevant to the growth narrative.

  • Amivantamab projected to lead US EGFR NSCLC revenue by 2036 A forecast shows J&J's amivantamab (with or without lazertinib) generating the highest US revenue in EGFR-mutated lung cancer by 2036, surpassing AstraZeneca's osimertinib. This reinforces J&J's oncology leadership and long-term sales potential.

    New analyst projection that highlights J&J's pipeline strength, a positive for future growth.

▲3▼1

J&J stays out of weight-loss race, boosts dividend, but talc appeal loss stings

  • J&J avoids GLP-1 race, focuses on oncology and devices CEO Joaquin Duato said J&J will not enter the GLP-1 weight-loss drug race, instead focusing on oncology and medical devices where it is strong. This avoids costly competition and supports steady growth, which can lift the stock.

    This is a new strategic decision that affects J&J's competitive position and future growth.

  • J&J raises dividend for 64th straight year and lifts outlook J&J increased its dividend 3.1% to $1.34 per share, marking 64 consecutive years of hikes, and raised full-year revenue guidance to $100.3–$101.3 billion. This signals confidence and appeals to income investors, supporting the stock price.

    This is a new event that directly boosts investor confidence and income appeal.

  • Planned orthopedics spinoff seen as catalyst to boost valuation J&J plans to spin off its DePuy Synthes orthopedics business within 18–24 months. Jim Cramer highlighted this as a catalyst to raise J&J's price-to-earnings multiple, similar to the Kenvue separation. This can unlock value and attract more investors.

    This is a new development that could re-rate the stock and is being actively discussed by influential investors.

  • Illinois court upholds $45 million talc verdict against J&J An Illinois appellate court affirmed a $45 million mesothelioma verdict against J&J and Kenvue, rejecting J&J's appeals. This increases legal risk and potential liabilities from talc lawsuits, which can weigh on the stock price.

    This is a new legal setback that adds to J&J's talc litigation overhang and could pressure the stock.

Q2 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

June 2026
▲3▼1

J&J's June: Pipeline Wins, $55B Investment, But CARVYKTI Slows

  • TALVEY Phase 3 Win and European Approval for Tecvayli J&J's TALVEY succeeded in a late-stage multiple myeloma trial, and Tecvayli won European approval. These advances strengthen J&J's cancer drug lineup and support future revenue growth.

    New clinical and regulatory wins are key positive drivers for J&J's growth outlook.

  • $55B U.S. Investment Plan and Firefly Bio Acquisition J&J announced a $55 billion U.S. investment plan aimed at double-digit growth and acquired Firefly Bio for $1 billion. These moves signal confidence and expand its innovative medicine pipeline.

    Major capital commitments and a strategic acquisition are new positive developments for J&J.

  • Talc Lawsuit Victory and Raised 2026 Guidance J&J won a talc lawsuit, reducing legal risk, and raised its 2026 guidance with a $100 billion revenue target. This boosts investor confidence in the company's financial trajectory.

    Legal relief and improved guidance are new positive catalysts for J&J's stock.

  • CARVYKTI Growth Deceleration and Pending Talc Lawsuits CARVYKTI's growth slowed to 57.4% from 63.2%, raising concerns about J&J's premium valuation. Over 67,000 talc lawsuits remain pending, and the stock's modest 6.4% gain suggests investors seek more proof of accelerating growth.

    These are new negative factors that temper the positive outlook and explain the stock's muted reaction.

▲4

J&J hits record on cancer wins, $1B deal, raised outlook

  • Talc cancer lawsuit win cuts legal risk A Los Angeles jury found J&J not negligent in a talc-cancer case. With over 67,000 similar lawsuits pending, any win lowers the chance of huge payouts and makes the stock less risky to own.

    This is a new legal victory that directly reduces a major overhang on JNJ shares.

  • Firefly Bio acquisition expands cancer pipeline J&J agreed to buy Firefly Bio for $1 billion in cash, gaining a new way to attack cancer cells. This adds to its pipeline and supports its goal of becoming the top cancer company by 2030, which can drive future sales.

    This is a new acquisition that strengthens JNJ's oncology growth story.

  • European approval for Tecvayli combo boosts sales Europe's drug regulator recommended expanding Tecvayli's use in multiple myeloma, based on strong trial results. This makes the drug available to more patients earlier, likely increasing sales and reinforcing J&J's leadership in blood cancer.

    This is a new regulatory win that expands a key drug's market.

  • Raised 2026 outlook and $100B revenue target J&J raised its 2026 revenue growth guidance to 6.1% and says it's on track to hit $100 billion in annual revenue for the first time. This signals confidence in accelerating growth, though the stock has only gained 6.4% since, suggesting investors want more proof.

    This is a new financial outlook that directly addresses JNJ's growth trajectory.

▲3▼1

J&J's oncology pipeline and $55B U.S. investment drive growth outlook

  • TALVEY Phase 3 win in multiple myeloma Positive Phase 3 results for TALVEY plus DARZALEX FASPRO showed superior progression-free survival in multiple myeloma, with up to 72% reduced risk of progression or death. This supports label expansion and could shift treatment guidelines, boosting J&J's oncology franchise and future sales.

    New clinical win directly strengthens J&J's cancer business, a key growth driver.

  • CEO commits $55B U.S. investment, targets double-digit growth CEO Joaquin Duato sees a path to double-digit growth and plans $55 billion in U.S. investment over four years, starting with a new biologics plant. This signals confidence in long-term growth and expands domestic manufacturing, which can lower supply risks and support earnings.

    New capital commitment and growth target show management's strategic direction and confidence.

  • New product launches and data expand treatment options J&J launched a dual-energy catheter ablation platform in Europe and presented new IMAAVY data reinforcing sustained disease control in myasthenia gravis. These advances broaden the medical device and pharma portfolios, supporting future revenue growth.

    New product launches and clinical data are fresh positive developments for J&J's business.

  • CARVYKTI growth deceleration raises valuation concerns CARVYKTI's year-over-year growth slowed to 57.4% from 63.2%, raising questions about its ramp-up. With J&J's stock trading near a 10-year high price-to-sales multiple, any further cooling could pressure the premium valuation and challenge the growth narrative.

    This is a real counterweight: a key growth drug showing slower momentum could weigh on the stock.

Euro/US Dollar FX Spot Rate (EURUSD.FOREX)

Latest
▼3▲1

Euro hits 17-month low as French debt fears and Fed rate bets boost dollar

  • French debt crisis and political gridlock sink euro Investors are dumping French bonds and stocks as public debt heads toward 120% of GDP, pushing the French-German bond spread to 141 basis points. This political and fiscal risk makes the euro less attractive, pushing EURUSD down to its lowest since May 2025.

    This is the main new force driving the euro lower this period.

  • US bond yields surge, Fed rate hike bets rise US 10-year Treasury yields jumped above 5.2%, the highest since 2002, as oil prices climbed and Fed officials backed further rate hikes. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is a key new driver of dollar strength this period.

  • Eurozone inflation beats forecasts, keeping ECB hike pressure alive Eurozone September inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which supports the euro by attracting global money into euro deposits.

    This is a new counterweight that could support the euro despite the negative drivers.

  • Energy shock and political risk weigh on euro outlook European gas prices above €80/MWh and the war in Iran disrupting LNG shipments are hurting Europe's economy. Meanwhile, far-right gains in Germany and France's political gridlock add uncertainty. These factors make the euro less attractive, pushing EURUSD down.

    This explains the broader negative backdrop for the euro this period.

Q3 2026
▲2▼1

Euro swings from two-month high to 17-month low as Fed hikes and French debt fears dominate

  • Euro hits two-month high on weak US jobs and split Fed The euro climbed to a two-month high near 1.166 as weak US jobs data and a divided Federal Reserve weakened the dollar, while solid eurozone activity and expected ECB rate hikes supported the currency.

    This explains the euro's peak during the period, driven by US dollar weakness and eurozone strength.

  • Euro plunges to 17-month low on Fed hikes and French debt The euro fell to a 17-month low as Federal Reserve rate hikes, 5.2% Treasury yields, French debt concerns, German far-right election gains, and energy shocks weighed heavily on the currency.

    This captures the main downward driver that pushed the euro to its lowest level in 17 months.

  • ECB rate hikes to 2.50% and resilient PMI offer partial support The European Central Bank raised rates to 2.50% and eurozone business activity remained resilient, providing only partial support to the euro amid broader negative forces.

    This shows the counterweight that limited the euro's decline, balancing the negative drivers.

September 2026
▼3▲1

Euro Falls to 17-Month Low as Dollar Strength and Eurozone Risks Dominate

  • Dollar Strength on Fed Hikes and High Yields The Fed raised rates to 3.75–4.00% and US 10-year yields topped 5.2%, pulling global money into dollar assets. This made the dollar more attractive and pushed the euro down.

    This is a key new force that drove EURUSD lower during the period.

  • Eurozone Political and Fiscal Risks Weigh on Euro France's debt neared 120% of GDP with widening bond spreads, and far-right gains in German elections raised concerns. These risks made investors wary of holding euros.

    New political developments added downward pressure on the euro.

  • Energy Shocks Hurt Europe's Growth Outlook Brent crude rose above $100 and natural gas above €80/MWh, raising costs for European businesses and consumers. This weakened the eurozone economy and weighed on the euro.

    Energy price spikes are a new negative factor for the euro.

  • ECB Hikes and Resilient Economy Support Euro Eurozone inflation hit 3.8%, prompting the ECB to raise rates to 2.50% and signal more tightening. The economy held up with PMI at 53.1, attracting some foreign capital.

    This positive force partially offset the euro's decline and is new this period.

▲2▼2

Eurozone data and ECB signals support euro, but US yields and politics weigh

  • Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

    This is new data showing eurozone resilience, which strengthens the euro.

  • ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

    New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

  • US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

    New US data and Fed comments drive dollar strength, a key counterweight to the euro.

  • German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

    New political and monetary developments that could undermine euro strength.

▲1▼1

ECB hikes and signals more, but Fed's first hike in three years lifts dollar

  • Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    Shows how far investors expect euro rates to rise, a key support for the euro.

  • Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

    The Fed's hike is the main new force pulling EURUSD down this period.

  • Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

    Energy prices are the underlying force driving both ECB tightening and euro weakness.

▲3▼1

ECB hikes to 2.50% and signals more, lifting euro despite US rate pushback

  • ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

    The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

  • Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

    Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

  • US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

    This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

  • Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

    Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

▲2▼1

ECB hike bets build on energy inflation; US intervention and Fed pushback cap euro

  • Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

    Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

  • Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    New forecasts of further ECB tightening extend the rate advantage that supports the euro.

  • US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

    This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

  • ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

    A new structural initiative that could affect future euro demand, though not an immediate price driver.

August 2026
▲2▼2

Euro Hits Two-Month High on Dollar Weakness, but Gains Capped

  • Dollar Weakness Lifts Euro Weak US jobs data and a split Fed cut September rate-hike odds, pushing the euro to a two-month high near 1.166. Treasury buybacks and Middle East de-escalation also weighed on the dollar.

    This is the main new driver of the euro's rise in August 2026.

  • Strong Eurozone Data and Hawkish ECB Support Euro Strong German trade and solid eurozone activity boosted the euro. The ECB stayed hawkish, with a September hike to 2.50% increasingly expected, making the euro more attractive.

    This is a new positive factor for the euro in August 2026.

  • US Intervention and Fed Comments Cap Euro US intervention selling euros to buy yen added euro supply and strained ECB cooperation. Fed Chair Warsh's Jackson Hole remarks and hot US PCE inflation revived US hike bets, strengthening the dollar.

    These new counterweights limited the euro's gains in August 2026.

  • Risks Tilt Against Euro Falling eurozone inflation expectations threatened ECB resolve, while stalled Iran talks and a possible US-Japan currency alliance kept risks tilted against the euro.

    These new risks prevented further euro strength in August 2026.

▼3▲1

ECB September hike bets build, but Fed pushback caps euro

  • ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    A near-certain ECB hike is the main force lifting the euro this period.

  • Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is the main new counterweight that pulled the euro back from its highs.

  • Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

    It shows the US side of the rate story that is capping the euro.

  • US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

    It is a real, ongoing drag on the euro that readers should not overlook.

▲3▼1

Euro hits two-month high as Fed hike bets fade and ECB stays hawkish

  • Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

    This is the main new force weakening the dollar and lifting the euro this period.

  • US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

    These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

  • Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

    New eurozone data and ECB comments support the euro side of the pair.

  • Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

    This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

July 2026
▲2▼2

Euro Rises on ECB Hawkishness and Weak US Data, but Gains Capped

  • ECB Hawkishness and Strong Eurozone Data Support Euro The European Central Bank kept a tough stance, with markets expecting more rate hikes as inflation stayed above target. Strong German and eurozone data, including GDP growth of 0.4% and high confidence, also lifted the euro.

    This explains a key force pushing the euro higher during the period.

  • Weak US Economic Data Weigh on Dollar Soft US inflation reports, weak GDP, and a Federal Reserve that held rates steady made the dollar less attractive. This helped push the euro to a six-week high near 1.1485.

    This highlights a major factor that weakened the dollar and supported the euro.

  • Oil Price Surge and Safe-Haven Demand Limit Euro Gains Oil prices above $100 due to Middle East tensions raised eurozone inflation but also hurt growth and increased bets on Fed rate hikes. This boosted dollar safe-haven demand, capping the euro's rise.

    This shows a counterweight that prevented larger euro gains.

  • Trade Tensions and Intervention Cap Euro Trump's tariff threats and a joint US-Japan intervention selling euros for yen added pressure. Eurozone inflation slowing to 2.8% in June also suggested the ECB might pause, limiting further euro strength.

    This points to other factors that restrained the euro's advance.

▲2▼1

ECB hike bets build as US data and yen intervention whipsaw the dollar

  • ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new force lifting the euro this period.

  • US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

    This is a new, direct supply shock to the euro that weighs on EURUSD.

  • US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

    US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

  • Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

    Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

▲2▼1

US jobs shock and euro-selling intervention drive euro to seven-week high

  • Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

    This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

  • US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

    This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

  • Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

    It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

▲3▼1

Fed holds, US data weak, eurozone inflation up — euro hits six-week high

  • Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

    A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

  • Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

    Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

  • Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

    Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

  • Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

    This is the main risk pulling EURUSD down, balancing the positive drivers.

▲2▼1

Oil spike revives ECB hike bets, but dollar strength keeps euro pinned near 1.14

  • ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new monetary policy event of the period and directly supports the euro.

  • German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

    Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

  • Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

    This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

  • SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

    It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

▲2▼1

US inflation cools, Fed hike bets fade; euro rebounds but oil risks cap gains

  • Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

    This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

  • Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

    Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

  • ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

    ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

  • Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

    This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

▲3

ECB hawkishness and Middle East tensions drive euro higher

  • ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

    This is a key new driver: ECB's hawkish stance strengthens the euro.

  • Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

    New escalation in Middle East tensions is a fresh factor pushing the dollar down.

  • Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

    New positive economic data from Germany supports the euro.

  • Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

    This shows a counterweight: while Fed bets ease, volatility risk remains.

Q2 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

June 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

▲1▼1

Eurozone inflation cools, ECB hike bets fade; weak US jobs lift euro

  • Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

    This is the main new force weakening the euro this period.

  • Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

    This is the main new force supporting the euro at the end of the period.

  • ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

    Shows the counterweight: ECB hawkishness supports the euro but may be fading.

▼3▲1

Euro hits one-year low as Fed hike bets and oil slump outweigh ECB

  • Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

    This is the main force pushing EURUSD down this period.

  • Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

    This new oil-driven shift in ECB expectations is a fresh negative for the euro.

  • ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

    Lagarde's stance is a new, direct driver of euro weakness this period.

  • Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

    This is the real counterweight that could stop or reverse the euro's fall.

▼2▲1

Hawkish Fed under Warsh drives dollar to one-year high, euro to three-month low

  • Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

    This is the dominant new force this period, directly driving the euro to multi-month lows.

  • ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

    Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

  • US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

    Shows a real counterweight to dollar strength, even if temporary.

  • Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

    Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

© 2026 MarketIVWhy